By Daniella Parra
Iovance Biotherapeutics said Amtagvi had a 52% response rate with two or less prior therapies and 73% overall disease control rate when used earlier in the treatment for advanced melanoma.
Amtagvi is a one-time T cell therapy for solid tumor cancer and the only approved treatment for patients with advanced melanoma who were previously treated with anti-PD-1 and targeted therapies, overall results showed 44% objective response rate and 73% disease control rate, the company said.
“The real-world response rate builds on existing clinical data and supports consideration of lifileucel as soon as possible after immune checkpoint inhibitor treatment,” said Lilit Karapetyan of the H. Lee Moffitt Cancer Center & Research Institute. “An overall response rate of 44% was observed in the full cohort, with a 52% response rate among patients treated in earlier lines of therapy.”
READ ALL ICR 2026 INTERVIEWS IN THE FOLLOWING LINK: ICR 2026
Register for our weekly newsletter HERE
Contact:
Click HERE to follow us on LinkedIn
